EU decides against new directive on GMP for excipients
This article was originally published in SRA
The European Commission has decided not to go ahead with legislation applying good manufacturing practice provisions to certain excipients after evidence showed it would lead to an increase in costs without providing any public health benefits.
You may also be interested in...
Coronavirus Notebook: EU Publishes CureVac Vaccine Contract, AZ and Pfizer Under Attack Over Supply Cuts
The European Ombudsman has opened an inquiry regarding the disclosure of vaccine contracts with other companies, and the European Commission is planning a “sharing mechanism” for vaccines bought by EU member states.
Australia will begin its coronavirus vaccination program with Comirnaty. The Oxford University/AstraZeneca vaccine is expected to be the next to receive approval.
Hungary is going its own way when it comes to coronavirus vaccines, but its decision to allow the emergency use of the Oxford University/AstraZeneca vaccine may be only a symbolic expression of the government’s growing impatience with the EU.